Opioid-induced constipation in advanced illness: Safety and efficacy of methylnaltrexone bromide

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 201-211

  Bader, S ^a   Jaroslawski, K ^a   Blum, H E ^a   Becker, G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Advanced illness; Methylnaltrexone; Opioid antagonist; Opioid induced constipation; Palliative care; receptor antagonist

Indexed keywords

17 METHYLNALTREXONE BROMIDE; ALVIMOPAN; LAXATIVE; MORPHINE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; OSMOTIC AGENT; PLACEBO;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CLINICAL PRACTICE; CONSTIPATION; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DYSPNEA; ECONOMIC ASPECT; FLATULENCE; HUMAN; HYPOTENSION; ILEUS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PAIN; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84860390516     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S4867     Document Type: Review

References (31)

1. Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer. May 2008;16(5):453-9.
2. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. Nov 2001;182(Suppl 5A):11S-18S.
3. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-71.
4. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 5 Jun 2009;155(1-3):11-7.
5. Holmes S. Use of a modifed symptom distress scale in assessment of the cancer patient. Int J Nurs Stud. 1989;26(1):69-79.
6. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or meth-ylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;1CD003448.
7. Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. Oct 2008;22(7):796-807.
8. Tavani A, Bianchi G, Ferretti P, Manara L. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 8 Dec 1980;27(23):2211-7.
9. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther. Jun 1986;237(3):945-9.
10. Manara L, Bianchi G, Fiocchi R, Notarnicola A, Peracchia F, Tavani A. Inhibition of gastrointestinal transit by morphine and FK 33-824 in the rat and comparative narcotic antagonist properties of naloxone and its N-methyl quaternary analog. Life Sci. 1982;31(12-13):1271-4.
11. Manara L, Bianchetti A. The central and peripheral infuences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol. 1985:25249-73.
12. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. Nov 2007;34(5):547-65.
13. Becker G, Blum HE. Novel opioid antagonists for opioid- induced bowel dysfunction and postoperative ileus. Lancet. 4 Apr 2009;373(9670):1198-206.
14. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol. 12 Mar 1982;78(3):255-61.
15. Kotake AN, Kuwahara SK, Burton E, McCoy CE, Goldberg LI. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica. Nov 1989;19(11):1247-54.
16. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. Apr 1997;61(4):467-75.
17. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. Apr 1996;59(4):469-75.
18. Foss JF, O'Connor MF, Yuan CS, Murphy M, Moss J, Roizen MF. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol. Jan 1997;37(1):25-30.
19. Yuan CS, Doshan H, Charney MR, O'connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. May 2005;45(5):538-46.
20. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. Mar 1985;24(3):181-91.
21. Gonenne J, Camilleri M, Ferber I, Burton D, Baxter K, Keyashian K, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol. Aug 2005;3(8):784-91.
22. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. Oct 1997;87(4):765-70.
23. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 19 Jan 2000;283(3):367-72.
24. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. May 2008;35(5):458-68.
25. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 29 May 2008;358(22):2332-43.
26. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39-46.
27. Karver. Methylnaltrexone treatment of opioid-induced constipation in cancer patients. ASCO meeting 2001, Abstracts.
28. Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. Jul 2010;40(1):e1-3.
29. Deibert P, Xander C, Blum HE, Becker G. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid. 2010;4247-58.
30. DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther. Jan 2008;117(1):162-87.
31. Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness-a cost-effectiveness analysis. Aliment Pharmacol Ther. Apr 2010;31(8):911-21.